Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death
October 24, 2026
October 24, 2026
BOSTON, Massachusetts, Oct. 24 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:
* * *
Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death
*
New analysis provides additional evidence on how the PROTEUS regimen compares with standard of care.
An international phase 3 clinical trial that treated patient . . .
* * *
Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death
*
New analysis provides additional evidence on how the PROTEUS regimen compares with standard of care.
An international phase 3 clinical trial that treated patient . . .